Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this HIV and hepatitis C drugmaker have returned -8% over the past month versus the Zacks S&P 500 composite's +3.1% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 0.1% over this period. Now the key question is: Where could the stock be h ...

During stock market ups and downs, identifying the next big players breeding massive value growth potentials is similar to finding a pearl in a vast ice lake. Among the multitude of options, certain market giants stand out; they are ready to embark on monumental rallies.These companies are strategically edging themselves for an unparalleled lead. They are armed with magna fundamentals and visionary strategies. Understanding these stocks’ underlying factors and potential becomes imperative to capture the upc ...

SOPA Images/LightRocket via Getty Images Gilead Sciences Incorporation’s (NASDAQ:GILD) stock price has not had a great week. As reported here on Seeking Alpha, the stock has traded in the red for the last seven days consecutively. Once the darling of the biotech world GILD, has seen better days. If we look back, we can see that the last five years haven’t been that great either. Seeking Alpha If we look back a little further we see that GILD stock has been dead money since 2015 when it traded over $100 ...

Gilead Sciences, Inc. (GILD) announced that it will acquire clinical-stage biopharmaceutical company, CymaBay Therapeutics, Inc. (CBAY) , for $32.50 per share in cash or a total equity value of $4.3 billion.Shares of CBAY surged 25.8% on the acquisition news as the offer price represents 27% of the company’s closing share price as of Feb 9, 2024.Financial Terms of the AcquisitionA wholly-owned subsidiary of Gilead will commence a tender offer to acquire all the outstanding shares of CymaBay’s common stock a ...

文章核心观点 - 公司被评为美国最公正企业之一,反映了公司长期致力于负责任运营,优先考虑利益相关方,包括患者、社区、员工和股东,努力创造一个更健康的世界 [1][2][3] - 公司的环境、社会和治理(ESG)战略旨在将公司定位为生物技术行业的首选雇主和合作伙伴,同时以可持续、负责任的方式为股东创造价值 [2][3] 公司ESG承诺和举措 - 通过促进卫生系统可持续性、加强基础设施、提供教育和财务支持等计划,扩大全球健康公平 [3] - 增加向低收入和中低收入国家提供药品的渠道,包括自愿许可公司的HIV、丙肝和COVID-19治疗药物 [3] - 创造一个能代表公司服务的多元化社区的包容性工作场所 [3] - 继续完善公司的环境可持续性计划,在碳排放、用水、废弃物和包装等方面取得进展 [3] 公司获奖和认可 - 连续第三年入选道琼斯可持续发展世界指数和北美指数,这突出了公司在全球最可持续公司评估中的表现 [3] - 公司的ESG报告遵循全球报告倡议组织、可持续会计准则委员会、气候相关财务信息披露工作组和联合国可持续发展目标等国际公认准则 [4]

Shares of Gilead Sciences (GILD -3.91%) are down 3.7% as of 3:30 p.m. ET Wednesday after the biopharmaceuticals giant announced mixed quarterly results relative to Wall Street's expectations.Why Gilead's "strong" year wasn't enoughGilead's fourth-quarter 2023 revenue declined 3.7% year over year to $7.115 billion, translating to non-GAAP (adjusted) net income of $1.72 per share (up from $1.67 per share in the same year-ago period). Analysts, on average, were expecting higher adjusted earnings of $1.76 per s ...

Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A common stock and Class B common stock as of April 9, 2024.The 3M Board of Directors today declared a dividend on the company's common stock of $1.51 per share for the first quarter of 2024. The dividend is payable March 12, 2024, to shareholders of record at the close of business on Feb. 16, 2024. 3M has paid di ...

财务表现 - Gilead Sciences, Inc.（GILD）第四季度的调整后每股收益为1.72美元，低于Zacks Consensus Estimate的1.76美元，但较去年同期的1.67美元有所增加[2] - 总收入为71亿美元，超过了Zacks Consensus Estimate的70亿美元，主要得益于Veklury（remdesivir）销售好于预期，由于2023年底住院人数增加，销售额下降了4%[3] - 营销费用为16亿美元，同比下降20.9%，去年同期记录了与Everest Medicines合作终止有关的Trodelvy的费用[15] 产品销售 - HIV产品销售下降2%至47亿美元，主要归因于通道混合导致的平均实现价格下降[5] - Biktarvy销售同比增长7%至31亿美元，但未达到Zacks Consensus Estimate和我们的模型估计的32亿美元[6] - Trodelvy乳腺癌药物销售同比增长53%至2.99亿美元，主要受到美国和欧洲需求增加的推动[12] - Veklury销售下降28%至7.2亿美元，主要由于COVID-19相关住院率降低[13] - 肝病产品组合销售同比持平，达到6.91亿美元，受不利定价动态影响，部分抵消了慢性丙型肝炎病毒和慢性丙型肝炎病毒产品的需求增加[8] 未来展望 - 2023年调整后每股收益从2022年的7.26美元下降至6.72美元，主要由于总成本和费用增加，以及Veklury销售下降[16] - 2024年产品销售预计在271亿至275亿美元之间，Veklury销售额预计约为13亿美元，调整后每股收益预计在6.85至7.25美元之间[17]

Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2023 Earnings Call Transcript February 6, 2024 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O’Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Leon Wang - Barclays Terrence Fl ...

For the quarter ended December 2023, Gilead Sciences (GILD) reported revenue of $7.12 billion, down 3.7% over the same period last year. EPS came in at $1.72, compared to $1.67 in the year-ago quarter.The reported revenue represents a surprise of +0.51% over the Zacks Consensus Estimate of $7.08 billion. With the consensus EPS estimate being $1.76, the EPS surprise was -2.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...